<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331357</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-05-06</org_study_id>
    <secondary_id>CCPPRB : 2006/04</secondary_id>
    <secondary_id>DGS : 2006/0212</secondary_id>
    <nct_id>NCT00331357</nct_id>
  </id_info>
  <brief_title>Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire</brief_title>
  <official_title>Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Angers</source>
  <brief_summary>
    <textblock>
      The objective of this study is to describe a paediatric population presenting an acute
      idiopathic thrombocytopenic purpura (ITP) and their evolution during their therapy in the
      region Pays de la Loire. The study will particularly evaluate the quality of life of these
      patients and their parents.

      The secondary objectives are to identify the predictive factors of the complications, the
      repetitions and the chronicity of the ITP, to estimate the principal parameters of the
      economic cost of therapy of the children suffering from ITP according to the protocol of
      therapy, set up in the region Pays de la Loire and the constitution of a blood sample
      collection which allow a better understanding of the physiopathology of this disease.

      It is about a prospective, multicentric clinical epidemiologic study of a paediatric cohort.
      Patients: 100 children from 0 to 17,99 years suffering from a first discovered ITP. The
      patients are not included if they present a serious, intercurrent, stabilized chronic
      pathology or not likely to modify the quality of life of the child and if they present a
      pathology other than the thrombopenia bringing into play the vital prognosis within a time
      lower than one year. These patients will be followed for 6 months according to the diagnosis
      of their ITP.

      During the 6 months follow-up of each patient, the study will not carry out more
      consultations, nor more blood tests than the usual follow-up of a child suffering from ITP.
      On the other hand, in addition to the J0 questionnaire, it will be requested to the patient
      and to his family to fill in the questionnaires of quality of life and way of life during the
      consultations of J8, 1 month, 3 months and 6 months. A check-up of autoimmunity at 6 months
      will be carried out if the thrombopenia persists (this check-up is usual and not-specific to
      the study). At the time of the blood test for the control of the platelets at J0 and 6
      months, an additional blood sample will be carried out: 5 ml are taken for the children of an
      age ≤ at 2 years, 10 ml from 2 to 4 years and 15 ml of blood for the children of an age &gt; at
      4 years. These blood samples are intended for the constitution of a blood sample collection.

      The protocol of therapy of the children suffering from ITP is homogeneous in all centers,
      this protocol being a consensus established by the network of Oncopaediatrics of the Pays de
      la Loire. The instituted treatment will be in function of the gravity of the ITP expressed in
      4 stages:

      Stage I: Platelets &gt; 20 gigas/L and absence of clinical signs. Stage II: Platelets &gt; 10
      gigas/L and hemorrhagic signs: haematomas, petechias or occasional epistaxis without
      repercussion on the daily life.

      Stage III: moderate. Platelets &gt; 10.000/mm3 and epistaxis with gauze pluggings or mucous
      lesions.

      Stage IV: severe. Platelets ≤ 10.000/mm3 or fall of 2 grs/dl of haemoglobin with bleedings:
      epistaxis, melaena or haemorrhages requiring a blood transfusion or an hospitalization and
      important changes in the activities of the daily life.

      Stages I and II do not receive any treatment and benefit from a simple monitoring.

      Stages III benefit from either a corticosteroid treatment (Méthylprednisolone or Prednisone)
      at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/day)
      or a monitoring according to the appreciation of the clinician.

      Stages IV profit in first intention from a treatment by Méthylprednisolone or Prednisone at
      the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/jour).

      The therapeutic attitude and the stadification belong to a regional consensus, established
      before the study, but each one can decide to apply a treatment according to the gravity of
      the clinical state of the child.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date>December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Acute Idiopathic Thrombocytopenic Purpura</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children 0 to 17,99 years

          -  suffering from a first discovered ITP

        Exclusion Criteria:

          -  serious, intercurrent, stabilized chronic pathology or not likely to modify the
             quality of life of the child

          -  pathology other than the thrombopenia bringing into play the vital prognosis within a
             time lower than one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle PELLIER, MD</last_name>
    <role>Study Director</role>
    <affiliation>UH of Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>isabelle PELLIER, MD</last_name>
    <email>IsPellier@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH of Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle PELLIER, MD</last_name>
      <email>Ispellier@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle PELLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier RIALLAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petronella RACHIERU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estelle DARVIOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49 325</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy SEGUIN, MD</last_name>
      <email>guy.seguin@ch-cholet.fr</email>
    </contact>
    <investigator>
      <last_name>Guy SEGUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francis CHOMIENNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvaine POIGNANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine RADET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie COURTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle GRIMAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of La Roche Sur Yon</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85 925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie GUILLEY, MD</last_name>
      <email>nathalie.guilley@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie GUILLEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique MEDINGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Laval</name>
      <address>
        <city>Laval</city>
        <zip>53 015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joachim BASSIL, MD</last_name>
      <email>joachim.bassil@chlaval.fr</email>
    </contact>
    <investigator>
      <last_name>Joachim BASSIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric PARIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72 037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eliane TARRAL, MD</last_name>
      <email>etarral@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Elaine TARRAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Chantal CHEVALLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44 093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline THOMAS, MD</last_name>
      <email>caroline.thomas@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>caroline THOMAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise MECHINAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadège CORRADINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptal of Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44 606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud BOUTET, MD</last_name>
      <email>a.boutet@ch-saintnazaire.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud BOUTET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2006</study_first_submitted>
  <study_first_submitted_qc>May 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>May 29, 2006</last_update_submitted>
  <last_update_submitted_qc>May 29, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2006</last_update_posted>
  <keyword>acute idiopathic thrombocytopenic purpura</keyword>
  <keyword>paediatric</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

